Cryptococcosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
SAN DIEGO– February 11, 2019– Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 11, 2019 Category: Pharmaceuticals Source Type: clinical trials

Vietnam Cryptococcal Retention in Care Study - Version 2.1
Conditions: HIV/AIDS; Cryptococcal Meningitis; Opportunistic Infections, HIV Related; Cryptococcosis; Mycosis; Opportunistic; Mycosis Fungoides Intervention: Other: Preemptive high-dose Fluconazole Sponsors: National Hospital for Tropical Diseases, Hanoi, Vietnam; Centers for Disease Control and Prevention; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam Completed - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 27, 2017 Category: Research Source Type: clinical trials